Breaks Categories: News

TuesdaySep 22, 2026 9:30 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Receives USPTO Notice of Allowance for LP-284 Blood Cancer Treatment Patent

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, announced that the United States Patent and Trademark Office ("USPTO") issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, covering methods of using LP-284 to treat mantle cell lymphoma ("MCL"), double-hit lymphoma ("DHL") and other blood cancers. The allowed claims include LP-284 as a monotherapy and in combination with several classes of anti-cancer agents. Once issued, the patent is expected to extend LP-284 intellectual property protection into 2042, adding method-of-use protection to Lantern existing composition-of-matter patent estate. Lantern Pharma (NASDAQ: LTRN) is evaluating LP-284 in an ongoing Phase 1a…

Continue Reading

FridaySep 18, 2026 11:10 am

BioMedNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) CEO Discusses GelrinC(R), U.S. Pivotal Study and European Commercialization on BioMedWire Podcast

Regentis Biomaterials (NYSE American: RGNT) Executive Chairman and CEO Dr. Ehud Geller joined the latest episode of The BioMedWire Podcast to discuss the company regenerative medicine platform and lead product GelrinC(R), which is being developed to treat cartilage injuries in the knee. Geller said GelrinC(R) is approved for marketing in Europe and is undergoing a U.S. pivotal clinical trial, with Regentis working to expand clinical sites and complete enrollment around year-end. He also discussed a U.S. market estimated at 470,000 currently untreated cases annually and the company efforts to advance European commercialization through discussions with distribution systems and major orthopedic…

Continue Reading

ThursdaySep 17, 2026 11:41 am

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap 

Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology therapies, announced it will host a live webinar Sept. 23 at 12:30 p.m. Eastern to present the business model, development roadmap and value proposition of Open-Medicine AI ("OMAI"), its wholly owned subsidiary developing a multi-agentic AI platform for end-to-end therapeutic development. The session, led by Panna Sharma, founder and CEO of Open-Medicine AI, will cover OMAI platform architecture, expansion beyond rare cancers into additional disease categories and therapeutic modalities and its planned subscription and enterprise licensing business model. To view the full press release, visit https://ibn.fm/MQ8Mc…

Continue Reading

ThursdaySep 17, 2026 11:31 am

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman & Renshaw initiated coverage of the company with a Buy rating and a $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma said the coverage is unpaid and that it provided no consideration or fees for the report. To view the full press release, visit https://ibn.fm/WNsHM About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

Continue Reading

ThursdaySep 17, 2026 11:22 am

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Joins €6.3 Million French Government-Funded DETECSEPS Sepsis Project 

VolitionRx Limited (NYSE American: VNRX) announced the official launch of the DETECSEPS project for the early detection of sepsis as part of the DETECSEPS Consortium, which is receiving €6.3 million, or approximately $7.3 million, in French government funding. The project is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique - Hôpitaux de Paris in partnership with Hospices Civils de Lyon, IDS France and Volition. Volition will provide the project’s sole biomarker, Nu.Q NETs, while IDS France will provide its automated analyzer to measure the biomarker. DETECSEPS will evaluate an early detection approach combining a routinely used clinical score with Volition’s Nu.Q NETs H3.1 blood…

Continue Reading

ThursdaySep 17, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Adds Capital Markets Veteran as CFO While Advancing BiTAC Oncology Pipeline

VERAXA has appointed Raju Willener as Chief Financial Officer, effective immediately. Willener brings more than 30 years of international experience spanning investment banking, corporate finance, asset management and capital markets. His appointment comes as VERAXA advances its proprietary BiTAC platform and a pipeline centered on antibody-drug conjugates and T-cell engagers. VERAXA has reported encouraging early data for its BiTAC technologies, including an in-vitro proof of concept for its BiTAC-ADC platform. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed Raju Willener as chief financial officer, adding a finance executive with more than three decades of…

Continue Reading

ThursdaySep 17, 2026 9:00 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTCQB: ETST) Uplists to OTCQB Venture Market

Earth Science Tech (OTCQB: ETST), a holding company with a diversified portfolio of distinct entities, announced its successful uplisting to the OTCQB Venture Market, effective for trading Sept. 17, 2026. The OTCQB requires companies to meet financial and reporting standards, undergo annual verification and comply with management certification requirements. To view the full press release, visit https://ibn.fm/oYq2M About Earth Science Tech, Inc. (ETST) Earth Science Tech, Inc. operates as a diversified holding company focused on the health and wellness sector. The Company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms,…

Continue Reading

WednesdaySep 16, 2026 11:00 am

BioMedNewsBreaks – Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Plans Phase 3 MDMA-Assisted Therapy Trial for PTSD

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced plans to initiate a Health Canada-authorized Phase 3 clinical trial in 2027 evaluating MDMA-assisted therapy for post-traumatic stress disorder (“PTSD”). The trial is intended to enroll up to 100 participants across multiple Canadian sites, focusing on veterans and current or former frontline workers, including military personnel, police, paramedics, firefighters and healthcare workers. Participants will receive Optimi’s synthetic MDMA HCl during two supervised sessions combining MDMA and psychotherapy, with the primary efficacy endpoint measuring changes in…

Continue Reading

TuesdaySep 15, 2026 12:29 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced its participation in the 3rd Annual ArcStone-Kingswood Growth Summit on Sept. 16, 2026, in Toronto, where Co-founder and Executive Co-chairman Anthony Durkacz will present the company’s recent milestones and future growth strategy. Quantum BioPharma recently announced that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS, allowing the company to begin Phase 2 trials of its patented, first-in-class multiple sclerosis program in patients with progressive MS. To…

Continue Reading

MondaySep 14, 2026 1:20 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) was featured in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlighting FDA clearance of the company’s Investigational New Drug (“IND”) application for Lucid-MS. According to the company, the approximately 15,000-page IND submission included a comprehensive package of pharmacology, toxicology and manufacturing data, with the clearance allowing Quantum BioPharma to move directly into a randomized, double-blind, placebo-controlled Phase 2 trial evaluating Lucid-MS in people with multiple sclerosis. Lucid-MS is the company’s patented…

Continue Reading